Clinical Trials Insight: 700048223
Phase of Trial: Phase I
Latest Information Update: 03 Apr 2011
At a glance
- Drugs Danoprevir; Peginterferon alfa-2a; Ribavirin; Ritonavir
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors InterMune; Roche
- 03 Apr 2011 Results presented at the 46th Annual Meeting of the European Association for the Study of the Liver.
- 15 Apr 2010 Results were presented at the 45th Annual Meeting of the European Association for the Study of the Liver, according to an InterMune media release.
- 29 Sep 2009 Status changed from planning to recruiting. Patient dosing has commenced, according to an Intermune media release.